Literature DB >> 20154722

Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells.

J J Molenaar1, M E Ebus, J Koster, E Santo, D Geerts, R Versteeg, H N Caron.   

Abstract

Almost all neuroblastoma tumors express excess levels of Cyclin D1 (CCND1) compared to normal tissues and other tumor types. Only a small percentage of these neuroblastoma tumors have high-level amplification of the Cyclin D1 gene. The other neuroblastoma tumors have equally high Cyclin D1 expression without amplification. Silencing of Cyclin D1 expression was previously found to trigger differentiation of neuroblastoma cells. Overexpression of Cyclin D1 is therefore one of the most frequent mechanisms with a postulated function in neuroblastoma pathogenesis. The cause for the Cyclin D1 overexpression is unknown. Here we show that Cyclin D1 overexpression results from transcriptional upregulation. To identify upstream regulators, we searched in mRNA profiles of neuroblastoma tumor series for transcription factors with expression patterns correlating to Cyclin D1. GATA3 most consistently correlated to Cyclin D1 in four independent data sets. We identified a highly conserved GATA3 binding site 27 bp upstream of the Cyclin D1 transcriptional start. Chromatin immune precipitation confirmed binding of GATA3 to the Cyclin D1 promoter. Overexpression of GATA3 induced Cyclin D1 promoter activity, which decreased after site-directed mutagenesis of the GATA3 binding site in the Cyclin D1 promoter. Silencing of GATA3 resulted in reduced Cyclin D1 promoter activity and reduced Cyclin D1 mRNA and protein levels. Moreover, GATA3 silencing caused differentiation that was similar to that caused by Cyclin D1 inhibition. These finding implicate GATA3 in Cyclin D1 overexpression in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154722     DOI: 10.1038/onc.2010.21

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  GATA-3 augmentation down-regulates Connexin43 in Helicobacter pylori associated gastric carcinogenesis.

Authors:  Xiaoming Liu; Ke Cao; Canxia Xu; Tingzi Hu; Li Zhou; Dan Cao; Jing Xiao; Ling Luo; Yinjie Guo; Yong Qi
Journal:  Cancer Biol Ther       Date:  2015-04-22       Impact factor: 4.742

2.  Loss of GATA3 in bladder cancer promotes cell migration and invasion.

Authors:  Yi Li; Hitoshi Ishiguro; Takashi Kawahara; Eiji Kashiwagi; Koji Izumi; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

3.  A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury.

Authors:  Irina V Grigorieva; Andre Oszwald; Elena F Grigorieva; Helga Schachner; Barbara Neudert; Tammo Ostendorf; Jürgen Floege; Maja T Lindenmeyer; Clemens D Cohen; Ulf Panzer; Christof Aigner; Alice Schmidt; Frank Grosveld; Rajesh V Thakker; Andrew Jackson Rees; Renate Kain
Journal:  J Am Soc Nephrol       Date:  2019-08-12       Impact factor: 10.121

4.  GATA Transcription Factors and Cancer.

Authors:  Rena Zheng; Gerd A Blobel
Journal:  Genes Cancer       Date:  2010-12

5.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

6.  Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression.

Authors:  Hiroyuki Hosokawa; Tomoaki Tanaka; Miki Kato; Kenta Shinoda; Hiroyuki Tohyama; Asami Hanazawa; Yuuki Tamaki; Kiyoshi Hirahara; Ryoji Yagi; Ikue Sakikawa; Atsushi Morita; Morio Nagira; Masha V Poyurovsky; Yutaka Suzuki; Shinichiro Motohashi; Toshinori Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

7.  DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis.

Authors:  Gemma Mayol; José I Martín-Subero; José Ríos; Ana Queiros; Marta Kulis; Mariona Suñol; Manel Esteller; Soledad Gómez; Idoia Garcia; Carmen de Torres; Eva Rodríguez; Patricia Galván; Jaume Mora; Cinzia Lavarino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas.

Authors:  Hardeep Kataria; Renu Wadhwa; Sunil C Kaul; Gurcharan Kaur
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

9.  Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma.

Authors:  Ali Rihani; Jo Vandesompele; Frank Speleman; Tom Van Maerken
Journal:  Cancer Cell Int       Date:  2015-07-30       Impact factor: 5.722

10.  The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells.

Authors:  Kondababu Kurakula; Mariska Vos; Iker Otermin Rubio; Goran Marinković; Reinhard Buettner; Lukas C Heukamp; Jan Stap; Vivian de Waard; Claudia M van Tiel; Carlie J M de Vries
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.